Biogen will stop selling its Alzheimer’s treatment Aduhelm.

The Food and Drug Administration's contentious approval of a questionable Alzheimer's drug is taking another hit.

Biogen is looking for a new CEO less than a year after its launch of its Alzheimer’s drug Aduhelm largely fizzled.

Medicare says it’s considering a cut in enrollee premiums, after officials stuck with an earlier decision to sharply limit coverage for a pricey new Alzheimer’s drug projected to drive up program costs.

The Centers for Medicare and Medicaid (CMS) are drastically cutting down on who can get Aduhelm, limiting it only to people enrolled in clinical trials.

Shares of Biogen have tumbled a day after regulators slapped strict limitations on coverage the drugmaker’s new Alzheimer’s disease treatment.

U.S. health secretary Xavier Becerra is ordering Medicare to reassess a big premium increase facing millions of seniors this year.

Biogen is slashing the price of its Alzheimer’s treatment months after the drug debuted to widespread criticism for an initial cost that can reach $56,000 annually.

A new $56,000-a-year Alzheimer’s medication that’s leading to one of the biggest increases ever in Medicare premiums is highlighting the limitations of President Joe Biden’s strategy for curbing prescription drug costs.

Sen. Bernie Sanders is asking the White House to cut back a big Medicare premium hike set to take effect in weeks and tied to a pricey Alzheimer’s drug whose benefits have been widely questioned.

Medicare’s “Part B” outpatient premium will jump by $21.60 a month in 2022, one of the largest increases ever.

A new Alzheimer’s drug from Biogen brought in only $300,000 in sales during its first full quarter on the market.

Medicare is launching a formal process to decide whether to cover the new Alzheimer’s drug, Aduhelm, whose $56,000-a-year price tag and unproven benefits have prompted widespread criticism and a congressional investigation.

The acting head of the Food and Drug Administration is calling for a government investigation into highly unusual contacts between her agency’s drug reviewers and the maker of a controversial new Alzheimer’s drug.

The Food and Drug Administration has approved new prescribing instructions that are likely to limit use of a controversial new Alzheimer's drug.

A new report says the $56,000 Alzheimer’s drug approved this week would raise Medicare premiums broadly.